CEBPZ and acute myeloid leukemia: In multivariable analyses adjusting for age, sex, AML ontogeny, CBF fusion gene, and additional cytogenetic or molecular alterations, treatment with GO remained associated with a favorable OS (HRadjusted 0.42, 95% CI 0.19–0.92, P = 0.031) and EFS (HRadjusted 0.65, 95% CI 0.44–0.96, P = 0.031; Table 2), while CIR was non-significantly reduced in GO vs. non-GO patients (HRadjusted 0.66, 95% CI 0.42–1.04, P = 0.07).